Lupron Depot
FDA Expands Zytiga for Late-Stage Prostate Cancer »
"The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
The FDA initially appr"...
Read the FDA Expands Zytiga for Late-Stage Prostate Cancer article »
Lupron Depot
PATIENT INFORMATION
Patients should be informed that:
- If they experience an allergic reaction to other drugs like LUPRON DEPOT, they should not use this drug.
- The most common side effects associated with LUPRON DEPOT are hot flashes, pain (especially joint pain and back pain), injection site pain and fatigue.
- LUPRON DEPOT may cause impotence.
- The increase in testosterone that occurs during the first weeks of therapy can cause an increase in urinary symptoms or pain.
- If they have metastatic cancer to the spine or urinary tract, they need close medical attention during the first weeks of therapy.
- They should notify their doctor if they develop new or worsened symptoms after beginning LUPRON DEPOT treatment.
Last reviewed on RxList: 8/3/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Lupron Depot Information
Lupron Depot - User Reviews
Lupron Depot User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Lupron Depot sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.
Updated & New
